miRNA Signatures in Endometrial Cancer: Implications for Oncogenesis and Polymerase Epsilon (POLE) Mutation Status

Area of Science:

• Molecular Biology
• Genomics
• Cancer Research

Background:

• MicroRNAs (miRNAs) are crucial gene expression regulators involved in oncogenic signaling.
• Endometrial cancer (EC) classification is evolving with the identification of POLE-mutated tumors, which have a better prognosis.
• Understanding miRNA dysregulation in EC, particularly in relation to POLE mutation status, is critical.

Purpose of the Study:

• To profile and compare miRNA expression in endometrial cancer tissues versus healthy controls.
• To investigate differences in miRNA expression between POLE-mutated and POLE-wild-type EC tumors.
• To identify potential miRNA biomarkers and therapeutic targets for endometrial cancer.

Main Methods:

• Quantitative PCR (qPCR) panels were used to profile miRNA expression in 40 EC patients and 20 healthy controls.
• POLE exonuclease domain mutations (P286R, V411L) were genotyped to stratify patients.
• Bioinformatic analyses included miRNA-mRNA interactions, target enrichment, and Gene Ontology (GO) pathway mapping, with validation against TCGA-UCEC data.

Main Results:

• Fifty significantly dysregulated miRNAs were identified between EC and healthy endometrium, including oncogenic hsa-miR-181a-5p and tumor-suppressive let-7 family members.
• POLE-mutated tumors exhibited a distinct miRNA signature with 19 significantly down-regulated miRNAs, such as let-7f-5p and hsa-miR-200b-3p.
• Bioinformatic analysis implicated key oncogenic regulators like MYC, TP53, and VEGFA as miRNA targets, and findings were validated using TCGA data.

Conclusions:

• Endometrial cancer is characterized by widespread miRNA deregulation.
• POLE-mutated EC tumors possess a unique global miRNA down-regulation signature.
• miRNAs show promise as complementary biomarkers for EC classification and as potential therapeutic targets.